NAT10 and neoplasm: Here, we engineered NP1192, a PROTAC degrader targeting NAT10.NP1192 achieved nearly 70% NAT10 degradation and a 26.8% lower IC50 than canonical NAT10 inhibitor Remodelin in cervical cancercells, outperforming Remodelin in antitumor effect in vivo, in vitro, and across three tumor organoids.